EUVIMEDEUVIMED entdecken
Crossref

Involvement of Janus kinase‐dependent Bcl‐xL overexpression in steroid resistance of group 2 innate lymphoid cells in asthma

Hayato Shimora, Masaya Matsuda iD, Yukiko Nakayama, Hiroto Maeyama, Ryunosuke Tanioka, Yoshiyuki Tanaka, Kazuyuki Kitatani, Takeshi Nabe iD

Immunology · 2024

DOI: 10.1111/imm.13805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Hayato Shimora und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan. Hauptthemen laut MEDLINE: Asthma, bcl-X Protein, Mice, Inbred BALB C, Lymphocytes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, Japan Agency for Medical Research and Development (AMED), Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mechanisms underlying the development of steroid resistance in asthma remain unclear. To establish whether as well as the mechanisms by which the activation of Janus kinases (JAKs) is involved in the development of steroid resistance in asthma, murine steroid‐resistant models of the proliferation of group 2 innate lymphoid cells (ILC2s) in vitro and asthmatic airway inflammation in vivo were analysed. ILC2s in the lungs of BALB/c mice were sorted and then incubated with IL‐33, thymic stromal lymphopoietin (TSLP), and/or IL‐7 with or without dexamethasone (10 nM), the pan‐JAK inhibitor, delgocitinib (1–10 000 nM), and/or the Bcl‐xL inhibitor, navitoclax (1–100 nM), followed by the detection of viable and apoptotic cells. The anti‐apoptotic factor, Bcl‐xL was detected in ILC2s by flow cytometry. As a steroid‐resistant asthma model, ovalbumin (OVA)‐sensitized BALB/c mice were intratracheally challenged with OVA at a high dose of 500 μg four times. Dexamethasone (1 mg/kg, i.p.), delgocitinib (3–30 mg/kg, p.o.), or navitoclax (30 mg/kg, p.o.) was administered during the challenges. Cellular infiltration into the lungs was analysed by flow cytometry. Airway remodelling was histologically evaluated. The following results were obtained. (1) Cell proliferation concomitant with a decrease in apoptotic cells was induced when ILC2s were cultured with TSLP and/or IL‐7, and was potently inhibited by dexamethasone. In contrast, when the culture with TSLP and IL‐7 was performed in the presence of IL‐33, the proliferative response exhibited steroid resistance. Steroid‐resistant ILC2 proliferation was suppressed by delgocitinib in a concentration‐dependent manner. (2) The culture with IL‐33, TSLP, and IL‐7 induced the overexpression of Bcl‐xL, which was clearly inhibited by delgocitinib, but not by dexamethasone. When ILC2s were treated with navitoclax, insensitivity to dexamethasone was significantly cancelled. (3) The development of airway remodelling and the infiltration of ILC2s into the lungs in the asthma model were not suppressed by dexamethasone, but were dose‐dependently inhibited by delgocitinib. Combination treatment with dexamethasone and either delgocitinib or navitoclax synergistically suppressed these responses. Therefore, JAKs appear to play significant roles in the induction of steroid resistance by up‐regulating Bcl‐xL in ILC2s. The inhibition of JAKs and Bcl‐xL has potential as pharmacotherapy for steroid‐resistant asthma, particularly that mediated by ILC2s.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Asthmabcl-X ProteinMice, Inbred BALB CLymphocytesDexamethasoneImmunity, InnateDrug ResistanceJanus KinasesAnimalsMiceLungFemaleCytokinesDisease Models, AnimalApoptosisCell ProliferationInterleukin-33Thymic Stromal LymphopoietinSulfonamides

Stichwörter der Autor:innen

Bcl‐xLJanus kinaseasthmagroup 2 innate lymphoid cellssteroid resistance

Substanzen

bcl-X ProteinDexamethasoneJanus KinasesCytokinesBcl2l1 protein, mouseInterleukin-33Thymic Stromal LymphopoietinSulfonamides

Autor:innen und Institutionen

  • Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan.

ORCID-Profile: Masaya Matsuda, Takeshi Nabe

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI
  • Japan Agency for Medical Research and Development (AMED)
  • Japan Society for the Promotion of Science

Zitieren

APA

Shimora, H., Matsuda, M., Nakayama, Y., Maeyama, H., Tanioka, R., Tanaka, Y., Kitatani, K., & Nabe, T. (2024). Involvement of Janus kinase‐dependent Bcl‐xL overexpression in steroid resistance of group 2 innate lymphoid cells in asthma. Immunology. https://doi.org/10.1111/imm.13805

Vancouver

Shimora H, Matsuda M, Nakayama Y, Maeyama H, Tanioka R, Tanaka Y, et al. Involvement of Janus kinase‐dependent Bcl‐xL overexpression in steroid resistance of group 2 innate lymphoid cells in asthma. Immunology. 2024. doi:10.1111/imm.13805

BibTeX
@article{Shimora2024,
  author = {Shimora, Hayato and Matsuda, Masaya and Nakayama, Yukiko and Maeyama, Hiroto and Tanioka, Ryunosuke and Tanaka, Yoshiyuki and Kitatani, Kazuyuki and Nabe, Takeshi},
  title = {Involvement of Janus kinase‐dependent Bcl‐xL overexpression in steroid resistance of group 2 innate lymphoid cells in asthma},
  journal = {Immunology},
  year = {2024},
  doi = {10.1111/imm.13805}
}
Kostenlos starten →